ZNF239. also known as ZKSCAN3. is a member of the zinc finger protein family characterized by the presence of Krüppel-associated box (KRAB) and SCAN domains. This nuclear protein functions as a transcription regulator, primarily repressing gene expression by recruiting chromatin-modifying complexes, such as histone deacetylases (HDACs), to specific DNA sequences. ZNF239 is implicated in diverse cellular processes, including cell proliferation, differentiation, and apoptosis, with emerging roles in cancer biology. Studies suggest its involvement in tumor suppression or oncogenesis, depending on cellular context, by modulating pathways like p53 signaling or autophagy.
Antibodies targeting ZNF239 are essential tools for investigating its expression patterns, subcellular localization, and molecular interactions. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP). Commercially available ZNF239 antibodies are typically validated for specificity and sensitivity across human, mouse, or rat samples. Research utilizing these antibodies has revealed ZNF239's differential expression in certain cancers, including hepatocellular carcinoma and colorectal cancer, highlighting its potential diagnostic or therapeutic relevance. However, functional studies remain ongoing to fully elucidate its regulatory networks and disease associations. Proper antibody validation via knockout controls or siRNA knockdown is critical due to shared epitopes among zinc finger proteins.